Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients

References

• Sadock B, Sadock V, Ruiz P. Synopsis of psychiatry. Philadelphia: Wolters Kluwer; 2015.
   Google Scholar
• Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28:550–553.
   PubMedGoogle Scholar
• Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964;40:10–27.
   PubMed Web of Science ®Google Scholar
• Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:1–11.
   Google Scholar
• Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11:166–176.
   PubMed Web of Science ®Google Scholar
• Koning JP, Tenback DE, Kahn RS, et al. Instrument measurement of lingual force variability reflects tardive tongue dyskinesia. J Med Eng Technol. 2010;34:71–77.
   PubMedGoogle Scholar
• Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121(Pt 11):2053–2066.
   PubMed Web of Science ®Google Scholar
• Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503–510.
   PubMed Web of Science ®Google Scholar
• Chong SA, Tay JA, Subramaniam M, et al. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009;29:5–8.
   PubMed Web of Science ®Google Scholar
• Yarden PE, Discipio WJ. Abnormal movements and prognosis in schizophrenia. Am J Psychiatry. 1971;128:317–323.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69:1580–1588.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Weiner E, Ball MP, et al. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23:436–441.
   PubMed Web of Science ®Google Scholar
• Shireen E. Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol. 2016;8:1–10.
   PubMedGoogle Scholar
• Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984;309:347–349.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–714.
   PubMed Web of Science ®Google Scholar
• Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;CD000203.
   PubMed Web of Science ®Google Scholar
• Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445–451.
   PubMed Web of Science ®Google Scholar
• Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27:1205–1215.
   PubMed Web of Science ®Google Scholar
• Shi J, Tan YL, Wang ZR, et al. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewing movement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacol Biochem Behav. 2016;148:53–58.
   PubMed Web of Science ®Google Scholar
• Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry. 1985;46:4–7.
   PubMed Web of Science ®Google Scholar
• Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723–733.
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–19.
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(Suppl B):102–106.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013;7:1329–1340.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151–156.
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71:463–474.
   PubMed Web of Science ®Google Scholar
• Pinninti NR, Faden J, Adityanjee A. Are second-generation antipsychotics useful in tardive dystonia? Clin Neuropharmacol. 2015;38:183–197.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Fahn S, Weiner WJ, et al. American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–469.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Steering committee on practice G. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
   PubMed Web of Science ®Google Scholar
• Gerlach J, Koppelhus P, Helweg E, et al. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50:410–424.
   PubMed Web of Science ®Google Scholar
• Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15:36S–44S.
   PubMed Web of Science ®Google Scholar
• Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1342–1348.
   PubMed Web of Science ®Google Scholar
• Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry. 2010;71:1226–1233.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985–996.
   PubMed Web of Science ®Google Scholar
• Lucetti C, Bellini G, Nuti A, et al. Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol. 2002;25:71–74.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Kusumi I, Koyama T. A case of tardive dystonia successfully managed with quetiapine. J Clin Psychiatry. 2004;65:583–584.
   PubMed Web of Science ®Google Scholar
• Ono S, Suzuki Y, Shindo M, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther. 2012;37:370–372.
   PubMed Web of Science ®Google Scholar
• Kang NR, Kim MD. Tardive dyskinesia: treatment with aripiprazole. Clin Psychopharmacol Neurosci. 2011;9:1–8.
   PubMedGoogle Scholar
• Rajarethinam R, Dziuba J, Manji S, et al. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry. 2009;10:416–419.
   PubMed Web of Science ®Google Scholar
• Takase M, Kanahara N, Oda Y, et al. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol. 2015;29:383–389.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137:16–21.
   PubMed Web of Science ®Google Scholar
• Gopal S, Xu H, Bossie C, et al. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. Int J Clin Pract. 2014;68:1514–1522.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Lin YH, Shen YC. Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate. J Neuropsychiatry Clin Neurosci. 2013;25:E46–7.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19:542–550.
   PubMed Web of Science ®Google Scholar
• Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–1380.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484.
   PubMed Web of Science ®Google Scholar
• Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23:176–185.
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27:95–99.
   PubMed Web of Science ®Google Scholar
• Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45:525–531.
   PubMed Web of Science ®Google Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331–373.
   PubMed Web of Science ®Google Scholar
• Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779–787.
   PubMed Web of Science ®Google Scholar
• Anderson KEF, Factor SA, Hauser RA; et al. A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD). American Psychiatric Association Annual Meeting; May 14–18, 2016.
   Google Scholar
• Citrome L. Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next? CNS Spectr. 2016;21:1–12.
   PubMed Web of Science ®Google Scholar
• Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.
   PubMed Web of Science ®Google Scholar
• Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.
   PubMed Web of Science ®Google Scholar
• Allen RM. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Biol Psychiatry. 1982;17:719–727.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, McEvoy JP. Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. J Clin Psychiatry. 1995;56:173.
   PubMed Web of Science ®Google Scholar
• Kabes J, Sikora J, Pisvejc J, et al. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry. 1982;17:185–192.
   PubMedGoogle Scholar
• Kabes J, Sikora J, Stary O, et al. Effectiveness of piracetam in tardive dyskinesia – double-blind cross-over controlled trial with a placebo. Cesk Psychiatr. 1983;79:339–345.
   PubMedGoogle Scholar
• Chaturvedi SK. Piracetam for drug-induced dyskinesia. J Clin Psychiatry. 1987;48:255.
   PubMed Web of Science ®Google Scholar
• Fehr C, Dahmen N, Klawe C, et al. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001;21:248–249.
   PubMed Web of Science ®Google Scholar
• Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:1031–1037.
   PubMed Web of Science ®Google Scholar
• McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology. 2003;61:419.
   PubMed Web of Science ®Google Scholar
• Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. 2006;29:265–268.
   PubMed Web of Science ®Google Scholar
• Konitsiotis S, Pappa S, Mantas C, et al. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21:1219–1221.
   PubMed Web of Science ®Google Scholar
• Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546–554.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to ginkgo biloba. Biol Psychiatry. 2012;72:700–706.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YQ, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107–111.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68:1648–1654.
   PubMed Web of Science ®Google Scholar
• Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;CD010501.
   PubMed Web of Science ®Google Scholar
• Bacher NM, Lewis HA. Low-dose propranolol in tardive dyskinesia. Am J Psychiatry. 1980;137:495–497.
   PubMed Web of Science ®Google Scholar
• Perenyi A, Farkas A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry. 1983;18:391–394.
   PubMed Web of Science ®Google Scholar
• Schrodt GR Jr., Wright JH, Simpson R, et al. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry. 1982;43:328–331.
   PubMed Web of Science ®Google Scholar
• Silver JM, Yudofsky SC, Kogan M, et al. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry. 1986;143:1290–1292.
   PubMed Web of Science ®Google Scholar
• Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord. 2012;27:1703.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, Verwey HA, Roels PR, et al. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1992;12:39–42.
   PubMed Web of Science ®Google Scholar
• Suddath RL, Straw GM, Freed WJ, et al. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav. 1991;39:743–745.
   PubMed Web of Science ®Google Scholar
• Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;CD000206.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577–585.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125–130.
   PubMed Web of Science ®Google Scholar
• Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis. 1993;181:649–651.
   PubMed Web of Science ®Google Scholar
• Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol. 2012;259:660–664.
   PubMed Web of Science ®Google Scholar
• Sharma H. Treatment of tardive dyskinesia by tetrabenazine, clonazepam and vitamin E. Indian J Psychiatry. 2009;51:162–163.
   PubMedGoogle Scholar
• Goff DC, Renshaw PF, Sarid-Segal O, et al. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry. 1993;33:700–706.
   PubMed Web of Science ®Google Scholar
• Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993;13:204–209.
   PubMed Web of Science ®Google Scholar
• Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans affairs cooperative study #394 study group. Arch Gen Psychiatry. 1999;56:836–841.
   PubMed Web of Science ®Google Scholar
• Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry. 1992;149:391–393.
   PubMed Web of Science ®Google Scholar
• Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117–1124.
   PubMed Web of Science ®Google Scholar
• Richardson MA, Small AM, Read LL, et al. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65:92–96.
   PubMed Web of Science ®Google Scholar
• Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16:438–441.
   PubMed Web of Science ®Google Scholar
• Peng LY, Lee Y, Lin PY. Electroconvulsive therapy for a patient with persistent tardive dyskinesia: a case report and literature review. J Ect. 2013;29:e52–4.
   PubMed Web of Science ®Google Scholar
• Kefalopoulou Z, Paschali A, Markaki E, et al. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009;119:269–273.
   PubMed Web of Science ®Google Scholar
• Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J (Engl). 2006;119:789–792.
   PubMed Web of Science ®Google Scholar